Parkinson’s Disease——Honorary Special Issue Commemorating the 80th Birthday of Professor Peter Riederer

A special issue of Biomolecules (ISSN 2218-273X). This special issue belongs to the section "Molecular Medicine".

Deadline for manuscript submissions: closed (31 December 2021) | Viewed by 8406

Special Issue Editors


E-Mail Website
Guest Editor
Department of Neurology, Ruhr-Universität Bochum, Bochum, Germany
Interests: Parkinson’s disease; neuron; neuroprotection; neuroregeneration; neuroinflammation; neurodegeneration; biomarkers; protein aggregation; alpha-synuclein; translational therapies
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Guest Editor
Leopoldina Hospital Schweinfurt, Schweinfurt, Germany
Interests: neurological diseases; neurological disorders; clinical neurology; neurodegeneration; movement disorders

Special Issue Information

Dear Colleagues,

This issue is dedicated to the 80th birthday of Professor Dr Peter Riederer.

He is one the most influential experimental researchers in the field of neurochemistry in psychiatry and neurology. His life time achievement is characterised by the continuous successful approach to combine clinical and experimental research.

This honorary issue in “Biomolecules” reflects this scientific principle and includes experimental findings and outcomes of clinical studies.

The editors wish Professor Riederer many further fruitful future years and thank him for his continuous support over the years.

Prof. Dr. Lars Tönges
Prof. Dr. Thomas Müller
Prof. Dr. Wilfried Kuhn
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomolecules is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Review

15 pages, 888 KiB  
Review
Update on CSF Biomarkers in Parkinson’s Disease
by Eun Hae Kwon, Sabrina Tennagels, Ralf Gold, Klaus Gerwert, Léon Beyer and Lars Tönges
Biomolecules 2022, 12(2), 329; https://doi.org/10.3390/biom12020329 - 18 Feb 2022
Cited by 36 | Viewed by 7414
Abstract
Progress in developing disease-modifying therapies in Parkinson’s disease (PD) can only be achieved through reliable objective markers that help to identify subjects at risk. This includes an early and accurate diagnosis as well as continuous monitoring of disease progression and therapy response. Although [...] Read more.
Progress in developing disease-modifying therapies in Parkinson’s disease (PD) can only be achieved through reliable objective markers that help to identify subjects at risk. This includes an early and accurate diagnosis as well as continuous monitoring of disease progression and therapy response. Although PD diagnosis still relies mainly on clinical features, encouragingly, advances in biomarker discovery have been made. The cerebrospinal fluid (CSF) is a biofluid of particular interest to study biomarkers since it is closest to the brain structures and therefore could serve as an ideal source to reflect ongoing pathologic processes. According to the key pathophysiological mechanisms, the CSF status of α-synuclein species, markers of amyloid and tau pathology, neurofilament light chain, lysosomal enzymes and markers of neuroinflammation provide promising preliminary results as candidate biomarkers. Untargeted approaches in the field of metabolomics provide insights into novel and interconnected biological pathways. Markers based on genetic forms of PD can contribute to identifying subgroups suitable for gene-targeted treatment strategies that might also be transferable to sporadic PD. Further validation analyses in large PD cohort studies will identify the CSF biomarker or biomarker combinations with the best value for clinical and research purposes. Full article
Show Figures

Figure 1

Back to TopTop